- Home
- PBFS vs RLMD Comparison
PBFS vs RLMD Comparison
Compare PBFS & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PBFS | RLMD |
|---|---|---|
| Founded | 1889 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 435.7M | 461.9M |
| IPO Year | 2019 | 2012 |
Fundamental Metrics
Financial Performance| Metric | PBFS | RLMD |
|---|---|---|
| Price | $18.08 | $4.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $12.40 |
| AVG Volume (30 Days) | 7.9K | ★ 936.8K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 36.07 | ★ 45.28 |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $15,814,000.00 | $13,070.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $50.39 | ★ N/A |
| Revenue Growth | 5.76 | ★ 154.83 |
| 52 Week Low | $12.64 | $1.45 |
| 52 Week High | $18.99 | $8.00 |
Technical Indicators
Market Signals| Indicator | PBFS | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 57.66 | 27.58 |
| Support Level | $16.73 | $3.98 |
| Resistance Level | $18.33 | $4.44 |
| Average True Range (ATR) | 0.52 | 0.19 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 31.19 | 4.61 |
Price Performance
Historical ComparisonAbout PBFS Pioneer Bancorp Inc.
Pioneer Bancorp Inc is involved in providing banking services. These services include Personal services such as Checking, Savings, eBanking Cards, and Business services such as Business Deposit and operating Accounts, Business eBanking, and Business loans. Some of the other services of the company include Government Banking, Wealth Management, Benefits Consulting and Insurance.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.